United States Value Set for the Functional Assessment of Cancer Therapy-General Eight Dimensions (FACT-8D), a Cancer-Specific Preference-Based Quality of Life Instrument

• DOI: 10.1007/s41669-023-00448-5
• Publication Date: 2023-12-07T07:02:21Z
• Authors: Madeleine T. King; D. A. Revicki; R. Norman; F. Müller; R.C. Viney; A. S. Pickard; D. Cella; J. W. Shaw; ; Neil Aaronson; John Brazier; David Cella; Daniel Costa; Peter Fayers; Peter Grimison; Monika Janda; Georg Kemmler; Madeleine T. King; Nan Luo; Helen McTaggart-C...; Rebecca Mercieca-...; Richard Norman; Dennis Revicki; Stuart Peacock; Simon Pickard; Donna Rowen; Galina Velikova; Rosalie Viney; Deborah Street; Tracey Young; Margaret-Ann Tait

To develop a value set reflecting the United States (US) general population's preferences for health states described by Functional Assessment of Cancer Therapy (FACT) eight-dimensions preference-based multi-attribute utility instrument (FACT-8D), derived from FACT-General cancer-specific health-related quality-of-life (HRQL) questionnaire. A US online panel was quota-sampled to achieve population sample representative sex, age (≥ 18 years), race and ethnicity. discrete choice experiment (DCE) used states. The valuation task involved choosing between pairs (choice-sets) varying levels FACT-8D HRQL dimensions survival (life-years). DCE included 100 choice-sets; each respondent randomly allocated 16 choice-sets. Data were analysed using conditional logit regression parameterized fit quality-adjusted life-year framework, weighted sociodemographic variables that non-representative population. Preference weights calculated as ratio HRQL-level coefficients coefficient. 2562 members opted in, 2462 (96%) completed at least one choice-set 2357 (92%) Pain nausea associated with largest weights, work sleep had more moderate sadness, worry support smallest weights. Within dimensions, severe generally larger preference-weighting algorithm estimate utilities responses questionnaire generated. worst state's −0.33. This provides defined use in evaluating oncology treatments.